NASDAQ:PRQRProQR Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ProQR Therapeutics NV Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.26 -0.19 (-3.49 %) (As of 05/22/2020 04:00 PM ET) Add Compare Share Today's Range$5.20Now: $5.26▼$5.5050-Day Range$4.50MA: $5.11▼$5.8752-Week Range$4.46Now: $5.26▼$13.28Volume75,180 shsAverage Volume153,858 shsMarket Capitalization$261.69 millionP/E RatioN/ADividend YieldN/ABeta0.5 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProQR Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.67, ProQR Therapeutics has a potential upside of 483.0% from its current price of $5.26.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesProQR Therapeutics has received 276 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProQR Therapeutics has received 278 “underperform” votes. (Add your “underperform” vote.)Community SentimentProQR Therapeutics has received 50.18% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote “Outperform” if you believe PRQR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions58.98% of the stock of ProQR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($1.39) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProQR Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProQR Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRQR Previous Symbol CUSIPN/A CIK1612940 Webwww.proqr.com Phone31-88-166-7000Debt Debt-to-Equity Ratio0.16 Current Ratio11.04 Quick Ratio11.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book2.49Profitability EPS (Most Recent Fiscal Year)($1.55) Net Income$-63,560,000.00 Net MarginsN/A Return on Equity-76.30% Return on Assets-59.26%Miscellaneous Employees118 Outstanding Shares49,750,000Market Cap$261.69 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:PRQR Rates by TradingView Receive PRQR News and Ratings via Email Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions How has ProQR Therapeutics' stock been impacted by COVID-19 (Coronavirus)? ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRQR shares have decreased by 24.9% and is now trading at $5.26. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of ProQR Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ProQR Therapeutics. When is ProQR Therapeutics' next earnings date? ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for ProQR Therapeutics. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics NV (NASDAQ:PRQR) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.02. View ProQR Therapeutics' earnings history. What price target have analysts set for PRQR? 4 equities research analysts have issued 1-year price objectives for ProQR Therapeutics' stock. Their forecasts range from $25.00 to $40.00. On average, they anticipate ProQR Therapeutics' share price to reach $30.67 in the next year. This suggests a possible upside of 483.0% from the stock's current price. View analysts' price targets for ProQR Therapeutics. Has ProQR Therapeutics been receiving favorable news coverage? News articles about PRQR stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ProQR Therapeutics earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutProQR Therapeutics. Who are some of ProQR Therapeutics' key competitors? Some companies that are related to ProQR Therapeutics include Phibro Animal Health (PAHC), Odonate Therapeutics (ODT), BioXcel Therapeutics (BTAI), Stoke Therapeutics (STOK), NextCure (NXTC), Athenex (ATNX), ImmunoGen (IMGN), Rhythm Pharmaceuticals (RYTM), Endo International (ENDP), Amphastar Pharmaceuticals (AMPH), Cue Biopharma (CUE), Gossamer Bio (GOSS), Omeros (OMER), Passage Bio (ORIC) and Collegium Pharmaceutical (COLL). View all competitors. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include Bioamber (BIOA), GALAPAGOS NV/S (GLPG), Corbus Pharmaceuticals (CRBP), Uniqure (QURE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Rigel Pharmaceuticals (RIGL). Who are ProQR Therapeutics' key executives? ProQR Therapeutics' management team includes the following people: Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 36)Ms. Smital Shah, Chief Bus. & Financial Officer (Age 43)Ms. Lisa A. Hayes, VP of Investor Relations & Corp. CommunicationsMr. Bart Klein, Sr. VP of Intellectual PropertyMr. Gerard Platenburg, Chief Innovation Officer & Chairman of Advisory Board (Age 55) What is ProQR Therapeutics' stock symbol? ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR." Who are ProQR Therapeutics' major shareholders? ProQR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (10.16%), Jennison Associates LLC (5.25%), DAFNA Capital Management LLC (2.49%), UBS Group AG (0.97%), BlackRock Inc. (0.88%) and Cowen AND Company LLC (0.71%). Which institutional investors are selling ProQR Therapeutics stock? PRQR stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Wellington Management Group LLP, BlackRock Inc., UBS Group AG, and Jennison Associates LLC. Which institutional investors are buying ProQR Therapeutics stock? PRQR stock was acquired by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, Morgan Stanley, DAFNA Capital Management LLC, JPMorgan Chase & Co., Aperio Group LLC, Two Sigma Investments LP, and Citigroup Inc.. How do I buy shares of ProQR Therapeutics? Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is ProQR Therapeutics' stock price today? One share of PRQR stock can currently be purchased for approximately $5.26. How big of a company is ProQR Therapeutics? ProQR Therapeutics has a market capitalization of $261.69 million. The biopharmaceutical company earns $-63,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. ProQR Therapeutics employs 118 workers across the globe. What is ProQR Therapeutics' official website? The official website for ProQR Therapeutics is www.proqr.com. How can I contact ProQR Therapeutics? ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
